Harrow Health price target lowered to $20 from $37 at Lake Street

Lake Street analyst Brooks O’Neil lowered the firm’s price target on Harrow Health to $20 from $37 and keeps a Buy rating on the shares after the company reported Q3 results below the firm’s forecast and consensus. The firm’s lower target reflects the shortfall and the reduction in its forward outlook, but it affirms its Buy rating as it still sees substantial upside from the current price of shares.